


3fu



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Inga Reynisdottir, Jeffrey R. Gulcher, Struan F. Grant and Gudmar Thorleifsson
Application No.: 10/820,226 Group Art Unit: 1634
Filed: April 7, 2004 Examiner: Not yet assigned
Confirmation No.: 6927
Title: HUMAN TYPE II DIABETES GENE - Kv CHANNEL-INTERACTING PROTEIN (KCHIP1) LOCATED ON CHROMOSOME 5

CERTIFICATE OF MAILING OR TRANSMISSION	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:	
3-15-06	<i>[Signature]</i>
Date	Signature
<i>Mercedis Murray</i>	
Typed or printed name of person signing certificate	

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

☐ under 37 CFR 1.129(a), or

(First/Second submission after Final Rejection)

☒ under 37 CFR 1.97(b), or

(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

☐ under 37 CFR 1.97(c) together with either:

☐ a Statement under 37 CFR 1.97(e), as checked below, or

☐ a \$180.00 fee under 37 CFR 1.17(p), or

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

☐ under 37 CFR 1.97(d) together with:

☐ a Statement under 37 CFR 1.97(e), as checked below, and

☐ a \$180.00 fee under 37 CFR 1.17(p), or

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

☐ under 37 CFR 1.97(i):

Applicant requests that the IDS and cited reference(s) be placed in the application file.

(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
 - ☒ Copies of the cited references (B1-B3 and C1-C11) are enclosed.
 - ☒ Copies of issued U.S. patents and published U.S. applications are not required and are not being provided.
 - ☐ Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
 - ☒ The listed references (A1, B1, and C1-C11) were cited in the enclosed International Search Reports in counterpart foreign applications.
 - ☐ The "concise explanation" requirement (non-English references) for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:
 - ☐ the explanation provided on the attached sheet.
 - ☐ the explanation provided in the Specification.
 - ☐ submission of the enclosed International Search Report.
 - ☐ submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
 - ☐ the enclosed English language abstract.

☒ Applicants request that the following non-published pending applications be considered:

Examiner's
Initials

_____ U.S. Patent Application No. 11/029,984, by Reynisdottir, *et al.*, filed January 5, 2005,
Docket No.: 2345.2049-007

_____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

_____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

Examiner

Date

- ☒ A copy of each above-cited application, including the current claims, is enclosed, except any application filed on or after June 30, 2003, which has been scanned into the PTO's Image File Wrapper (IFW) system and is available to the examiner.
- ☐ A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

- ☐ A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- ☐ Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.
- ☒ Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Pamela A. Torpey
Pamela A. Torpey

Registration No.: 45,736

Telephone: (978) 341-0036

Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated:

March 15, 2006

APPLICATION NO.
10/820,226

FIRST NAMED INVENTOR
Inga Reynisdottir

FILING DATE
April 7, 2004

March 14, 2006

EXAMINER
Not yet assigned

CONFIRMATION NO.
6927

GROUP
1634

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

[illegible]

EXAMINER

DATE CONSIDERED

[illegible]

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION March 14, 2006 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2345.2049-005		APPLICATION NO. 10/820,226	
	FIRST NAMED INVENTOR Inga Reynisdottir		FILING DATE April 7, 2004	
	EXAMINER Not yet assigned	CONFIRMATION NO. 6927	GROUP 1634	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C1	Kroese, M., <i>et al.</i> , "Genetic Tests and Their Evaluation: Can We Answer the Key Questions?," <i>Genetics in Medicine</i> , 6(6): 475-480 (Nov/Dec 2004).
C2	Lucentini, J., "Gene Association Studies Typically Wrong," <i>The Scientist</i> , 18: 20 (Dec 2004).
C3	Page, G.P., <i>et al.</i> , "'Are We There Yet?': Deciding When One Has Demonstrated Specific Genetic Causation in Complex Diseases and Quantitative Traits," <i>Am. J. Hum. Genet.</i> , 73: 711-719 (2003).
C4	Van Hoorick, Diane, <i>et al.</i> , "Differential Modulation of Kv4 Kinetics by KCHIP1 Splice Variants," <i>Molecular and Cellular Neuroscience</i> , 24: 357-366 (2003).
C5	Reynisdottir, I., <i>et al.</i> , "Localization of a Susceptibility Gene for Type 2 Diabetes to Chromosome 5q34-q35.2," <i>Am. J. Hum. Genet.</i> , 73: 323-335 (2003).
C6	Martin, L.J., <i>et al.</i> , "A Quantitative Trait Locus Influencing Type 2 Diabetes Susceptibility Maps to a Region on 5q in an Extended French Family," <i>Diabetes</i> , 51: 3568-3572 (2002).
C7	Lindgren, C.M., <i>et al.</i> , "Contribution of Known and Unknown Susceptibility Genes to Early-Onset Diabetes in Scandinavia," <i>Diabetes</i> , 51: 1609-1617 (2002).
C8	Pezzolesi, M.G., <i>et al.</i> , "Examination of Candidate Chromosomal Regions for Type 2 Diabetes Reveals a Susceptibility Locus on Human Chromosome 8p23.1," <i>Diabetes</i> , 53: 486-491 (2004).
C9	Takimoto, K., <i>et al.</i> , "Palmitoylation of KchIP Splicing Variants is Required for Efficient Cell Surface Expression of Kv4.3 Channels," <i>The Journal of Biological Chemistry</i> , 277(30): 26904-26911 (2002).
C10	An, W.F., <i>et al.</i> , "Modulation of A-Type Potassium Channels by a Family of Calcium Sensors," <i>Nature</i> , 403: 553-556 (2000).
C11	(XP-002368358) Reynisdottir, I., <i>et al.</i> , "A Gene Encoding the Kv Channel Interacting Protein 1 (KChIp1) Confers Risk of Type 2 Diabetes Mellitus," XP002368358, Database Accession Number PREV200600017202 abstract & DIABETES, 54(Suppl. 1): A80, 65 th Annual Meeting of the American Diabetes Associate, San Diego, CA, USA, June 10-14, 2005, ISSN: 0012-1797.

EXAMINER	DATE CONSIDERED
----------	-----------------